Organon & Co.
OGN · XNYSCIK 1821825fmd_0NCXM0ENEDDHKGWRB7RDM6TMVPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 7,777 | 6,532 | 6,304 | 6,174 | 6,263 | 6,403 | 6,216 |
| Cost of revenue | 2,274 | 2,119 | 2,382 | 2,294 | 2,515 | 2,688 | 2,903 |
| Gross profit | 5,503 | 4,413 | 3,922 | 3,880 | 3,748 | 3,715 | 3,313 |
| Research and development | 220 | 210 | 339 | 471 | 528 | 469 | 366 |
| Selling, general and administrative | 1,443 | 1,356 | 1,668 | 1,704 | 1,893 | 1,760 | 1,721 |
| Interest expense | 0 | 0 | 258 | 422 | 527 | 520 | 504 |
| Income before taxes | 3,696 | 2,752 | 1,529 | 1,122 | 673 | 807 | 425 |
| Income tax expense | 390 | 496 | 178 | 205 | (350) | (57) | 238 |
| Net income from continuing operations | 3,306 | 2,256 | 1,351 | 917 | 1,023 | 864 | 187 |
| Net income | 3,218 | 2,160 | 1,351 | 917 | 1,023 | 864 | 187 |